港股異動 | 微創機器人-B繼續大漲14% 6日漲幅近乎翻倍
格隆匯10月21日丨微創機器人-B(2252.HK)再度拉昇漲超14%,近6日漲幅近乎翻倍,盤中最高報32.25港元創逾2個月新高價,總市值重回300億港元上方。近期,醫療行業頻吹暖風。受集採預期利好政策集中釋放,貼息貸款以及醫藥板塊低配等因素影響,醫療器械和科研裝備估值逐步迎來重估。公司旗下自研圖邁®四臂腔鏡手術機器人已完成300例機器人輔助臨牀驗證手術,將持續獲益政策效應帶來的利好。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.